Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results

NAII posts a sharp quarterly loss as sales and margins drop steeply.

What the company is saying

Natural Alternatives International, Inc. (NASDAQ:NAII) reports a net loss of $2.5 million, or ($0.41) per diluted share, for the first quarter of fiscal 2027, highlighting a significant deterioration from last year's $0.3 million loss. The company attributes the 25.5% year-over-year sales decline to reduced orders from major customers facing excess inventory and delayed product launches, only partially offset by new customer launches. Management emphasizes that the operating loss stemmed from lower sales volume in the private-label contract manufacturing segment, which drove down gross margins due to underutilized factory capacity. The company notes a 54% increase in CarnoSyn® beta-alanine royalty, licensing, and raw material sales to $2.6 million, primarily from higher TriBsyn® sales, but this was not enough to offset broader declines. To address these challenges, NAII has consolidated most U.S. production into its Vista facility, started the process to sell its Carlsbad facility, and launched a strategic review exploring options such as mergers, acquisitions, joint ventures, or a sale. Chairman and CEO Mark A. Le Doux acknowledges the disappointing results but expresses cautious optimism based on recent customer engagement and ongoing research initiatives. The tone is candid and focused on operational and strategic responses to the downturn.

What the data suggests

The reported net loss of $2.5 million on $28.1 million in sales marks a steep decline from the prior year's $0.3 million loss on $37.7 million in sales. Gross profit fell to $1.3 million, or 4.5% of sales, down from $4.4 million and 11.7% a year ago, indicating severe margin compression. Private-label contract manufacturing sales dropped 29.1% to $25.6 million, confirming the company's claim of customer-driven volume declines. CarnoSyn®-related revenue rose 54% to $2.6 million, but this segment remains too small to offset the core business contraction. Working capital halved to $14.7 million from $27.7 million over the quarter, and cash, cash equivalents, and restricted cash decreased to $6.7 million from $7.5 million. Outstanding borrowings on the credit facility stand at $6.3 million, with $11.8 million of remaining capacity. The company's explanation for the downturn—customer inventory overhang and delayed launches—is plausible given the magnitude of the sales drop, but no quantitative breakdown by customer or product is provided. The decision to consolidate operations and seek strategic alternatives signals management's recognition of structural challenges. The data shows a business under acute financial stress, with only modest relief from cost-cutting and secondary revenue streams.

Analysis

The announcement is candid about deteriorating financial performance, with a significant year-over-year decline in sales and profitability, and does not attempt to overstate progress or prospects. Most claims are realised and supported by detailed numerical disclosures, including net loss, sales, gross profit, and liquidity metrics. Forward-looking statements are limited to process-oriented actions (facility sale, strategic review, research expansion) rather than concrete projections of turnaround or growth. There is no exaggerated language or narrative inflation; management commentary acknowledges challenges and frames future actions as exploratory or in-process, not as imminent solutions. No large capital outlay is paired with promises of long-term, uncertain returns. The gap between narrative and evidence is minimal, and the tone is appropriately cautious given the results.

Risk flags

• ●The company faces acute operational risk from a 25.5% year-over-year sales decline and a 29.1% drop in private-label contract manufacturing sales, which are its primary revenue source. This contraction is attributed to customer inventory issues and delayed launches, suggesting demand instability that may persist beyond the current quarter.
• ●Gross margin deterioration from 11.7% to 4.5% signals underutilized capacity and limited pricing power, raising concerns about the company's ability to return to profitability without a substantial rebound in volumes or a successful cost restructuring.
• ●Liquidity risk is elevated as working capital fell from $27.7 million to $14.7 million in a single quarter, and cash balances declined to $6.7 million. While the company retains $11.8 million in borrowing capacity, ongoing losses could erode this cushion quickly if sales do not recover.
• ●Strategic uncertainty is high as the company has only begun the process to sell a facility and is exploring a wide range of strategic alternatives, including a possible sale of the company. No binding agreements or timelines are disclosed, so outcomes and timing remain highly uncertain.

Bottom line

NAII's first quarter fiscal 2027 results confirm a sharp deterioration in sales, margins, and profitability, with a net loss of $2.5 million and sales down 25.5% year-over-year. The company's core private-label manufacturing business is under pressure from customer inventory overhang and delayed product launches, and while CarnoSyn®-related revenues grew, they are not large enough to offset the decline. Liquidity is tightening, with working capital and cash balances dropping sharply, and the company is now reliant on further credit facility drawdowns or asset sales to maintain flexibility. Management is candid about the challenges and has initiated operational consolidation and a strategic review, but no concrete recovery or transaction is yet in place. Investors should see this as a business in distress, with any turnaround or strategic outcome likely to take months and subject to considerable uncertainty. The most important takeaway is that near-term financial risks are high, and the company's future direction hinges on the outcome of its ongoing strategic review and ability to stabilize core sales.

Announcement summary

(NASDAQ:NAII) Natural Alternatives International, Inc. reported a net loss of $2.5 million, or ($0.41) per diluted share, on net sales of $28.1 million for the first quarter of fiscal year 2027. This compares to a net loss of $0.3 million, or ($0.05) per diluted share, on net sales of $37.7 million in the first quarter of the prior fiscal year. Net sales for the three months ended September 30, 2026, decreased by $9.6 million, or 25.5%, to $28.1 million from $37.7 million in the comparable prior year period. Private-label contract manufacturing sales declined 29.1% to $25.6 million, primarily due to decreased orders from several larger customers with excess inventory and delayed product launches, partially offset by new customer product launches. CarnoSyn® beta-alanine royalty, licensing, and raw material sales revenue increased 54.0% to $2.6 million, compared to $1.7 million in the prior year period, driven by increased TriBsyn® product sales and partially offset by a decrease in instant release CarnoSyn® raw material sales. The company experienced a loss from operations of $2.6 million during the three months ending September 30, 2026, mainly due to decreased sales volume in the private-label contract manufacturing segment, which led to lower gross margins from reduced factory capacity utilization. This operating loss was partially offset by lower selling, general and administrative expenses, primarily due to decreased employee compensation. To improve manufacturing capacity utilization, profitability, and reduce operating costs, NAI consolidated most U.S. production operations into its Vista, CA manufacturing facility and began the process to sell its Carlsbad, CA manufacturing facility. The company has initiated a comprehensive review process to explore strategic alternatives, including potential mergers, acquisitions, joint ventures, or a sale of the company. As of September 30, 2026, NAI had cash, cash equivalents, and restricted cash of $6.7 million and working capital of $14.7 million, compared to $7.5 million and $27.7 million, respectively, as of June 30, 2026. As of September 30, 2026, the company had $11.8 million of borrowing capacity on its credit facility, with $6.3 million in outstanding borrowings. Gross profit for the quarter was $1.3 million, or 4.5% of net sales, compared to $4.4 million, or 11.7% of net sales, in the prior year period. Selling, general and administrative expenses were $3.8 million, or 13.7% of net sales, compared to $4.1 million, or 10.9% of net sales, in the prior year period. Other expense, net, was $0.2 million, compared to $0.5 million in the prior year period. Loss before taxes was $2.7 million, compared to $0.2 million in the prior year period. Income tax benefit was $0.3 million, compared to an expense of $0.1 million in the prior year period. Weighted average common shares outstanding for both basic and diluted calculations were 6,075,000 for the quarter ended September 30, 2026, and 6,007,000 for the prior year period. As of September 30, 2026, total assets were $114.5 million and total liabilities were $67.3 million, with stockholders’ equity of $47.2 million. Accounts receivable, net, were $12.4 million and inventories, net, were $28.2 million as of September 30, 2026. Accounts payable and accrued liabilities were $19.8 million, the line of credit was $6.3 million, and the mortgage note payable was $10.8 million as of September 30, 2026. Operating lease liability was $30.5 million as of September 30, 2026. Mark A. Le Doux, Chairman and Chief Executive Officer, stated that the disappointing results were due to customer reticence to meet forecast commitments, but recent meetings have encouraged the company to expand research and formulation efforts, including combinations of CarnoSyn® with popular peptides. The company is actively reviewing options to improve manufacturing architecture, overhead absorption, and liquidity, and remains committed to right sizing U.S. facilities and promoting its IP estate in new applications. An updated investor presentation will be posted to the investor relations page on the company website.

Disagree with this article?